Payment overview · 2025
General Payments
$136.15
5 reported records · 5 companies
Healthcare provider profile · identity verified
Anu Garg, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Geriatric Medicine · TOLEDO, OH · NPI 1336316306
Verified facts
What the public records show
CMS Open Payments records show Anu Garg, MD received $136.15 in general payments during 2025 across 5 reported records.
Janssen Pharmaceuticals, Inc accounted for 24.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Invega Sustenna.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INVEGA SUSTENNA as an associated drug or biological on 39068 records involving 11966 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Invega Sustenna by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 121 claims for Xarelto by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Nuedexta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $32.63 | 24.0% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $32.27 | 23.7% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $29.23 | 21.5% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $21.16 | 15.5% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $20.86 | 15.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $103.88 | 4 |
| Education | $32.27 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| INVEGA SUSTENNA Normalized: invega sustenna |
Drug | Janssen Pharmaceuticals, Inc | $32.63 | 1 | 2025 |
Source payment records
|
|||||
| INVEGA TRINZA Normalized: invega trinza |
Drug | Janssen Pharmaceuticals, Inc | $32.63 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $32.27 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $21.16 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $20.86 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| INVEGA SUSTENNA invega sustenna |
2025 | Invega Sustenna | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | INVEGA SUSTENNA open payments reported associated product |
CMS Open Payments — General Payments 39068 supporting records · 11966 recipient NPIs · example record 1174223262 |
Invega Sustenna · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
121 | 13 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 555 | 111 |
| Eliquis | Apixaban | 496 | 55 |
| Gabapentin | Gabapentin | 427 | 64 |
| Potassium Chloride | Potassium Chloride | 358 | 65 |
| Furosemide | Furosemide | 347 | 63 |
| Sertraline Hcl | Sertraline Hcl | 340 | 71 |
| Levothyroxine Sodium | Levothyroxine Sodium | 324 | 66 |
| Amlodipine Besylate | Amlodipine Besylate | 311 | 76 |
| Lisinopril | Lisinopril | 289 | 61 |
| Metoprolol Succinate | Metoprolol Succinate | 289 | 61 |
| Pantoprazole Sodium | Pantoprazole Sodium | 266 | 51 |
| Quetiapine Fumarate | Quetiapine Fumarate | 261 | 37 |
| Mirtazapine | Mirtazapine | 214 | 54 |
| Trazodone Hcl | Trazodone Hcl | 206 | 45 |
| Carvedilol | Carvedilol | 203 | 35 |
| Donepezil Hcl | Donepezil Hcl | 203 | 37 |
| Buspirone Hcl | Buspirone Hcl | 193 | 29 |
| Olanzapine | Olanzapine | 193 | 32 |
| Metoprolol Tartrate | Metoprolol Tartrate | 183 | 44 |
| Tamsulosin Hcl | Tamsulosin Hcl | 164 | 34 |
| Duloxetine Hcl | Duloxetine Hcl | 162 | 24 |
| Divalproex Sodium | Divalproex Sodium | 156 | 34 |
| Clopidogrel | Clopidogrel Bisulfate | 155 | 30 |
| Bumetanide | Bumetanide | 151 | 29 |
| Metformin Hcl | Metformin Hcl | 146 | 33 |
| Omeprazole | Omeprazole | 143 | 36 |
| Levetiracetam | Levetiracetam | 142 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 141 | 19 |
| Memantine Hcl | Memantine Hcl | 124 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 121 | 24 |
| Xarelto | Rivaroxaban | 121 | 13 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 117 | 17 |
| Spironolactone | Spironolactone | 113 | 21 |
| Myrbetriq | Mirabegron | 109 | suppressed |
| Losartan Potassium | Losartan Potassium | 103 | 33 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 103 | 14 |
| Lactulose | Lactulose | 99 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 97 | 23 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 93 | 24 |
| Simvastatin | Simvastatin | 93 | 20 |
| Prednisone | Prednisone | 90 | 32 |
| Pravastatin Sodium | Pravastatin Sodium | 87 | 12 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 86 | 23 |
| Fluoxetine Hcl | Fluoxetine Hcl | 85 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 81 | 19 |
| Amiodarone Hcl | Amiodarone Hcl | 80 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 78 | 14 |
| Risperidone | Risperidone | 71 | suppressed |
| Levofloxacin | Levofloxacin | 68 | 28 |
| Warfarin Sodium | Warfarin Sodium | 68 | suppressed |
| Famotidine | Famotidine | 66 | 18 |
| Ropinirole Hcl | Ropinirole Hcl | 66 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 65 | 11 |
| Cephalexin | Cephalexin | 62 | 36 |
| Finasteride | Finasteride | 62 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 62 | 23 |
| Azithromycin | Azithromycin | 61 | 37 |
| Montelukast Sodium | Montelukast Sodium | 59 | suppressed |
| Aripiprazole | Aripiprazole | 58 | 11 |
| Rivastigmine | Rivastigmine | 58 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 54 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 53 | 24 |
| Trulicity | Dulaglutide | 50 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 49 | 14 |
| Ondansetron Hcl | Ondansetron Hcl | 49 | 36 |
| Tradjenta | Linagliptin | 48 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 47 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 46 | 27 |
| Jardiance | Empagliflozin | 46 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 45 | suppressed |
| Meloxicam | Meloxicam | 44 | suppressed |
| Admelog Solostar | Insulin Lispro | 43 | 12 |
| Allopurinol | Allopurinol | 43 | 15 |
| Incruse Ellipta | Umeclidinium Bromide | 43 | 11 |
| Latanoprost | Latanoprost | 43 | 13 |
| Oxcarbazepine | Oxcarbazepine | 43 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 41 | 22 |
| Albuterol Sulfate | Albuterol Sulfate | 40 | 20 |
| Benztropine Mesylate | Benztropine Mesylate | 40 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 40 | 20 |
| Januvia | Sitagliptin Phosphate | 40 | suppressed |
| Topiramate | Topiramate | 40 | suppressed |
| Lorazepam | Lorazepam | 39 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 38 | 25 |
| Entresto | Sacubitril/Valsartan | 37 | suppressed |
| Novolog Flexpen | Insulin Aspart | 36 | 18 |
| Calcitriol | Calcitriol | 35 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 35 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 34 | suppressed |
| Paliperidone Er | Paliperidone | 33 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 33 | 11 |
| Farxiga | Dapagliflozin Propanediol | 32 | suppressed |
| Meropenem | Meropenem | 32 | 11 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 32 | 23 |
| Tramadol Hcl | Tramadol Hcl | 31 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 30 | 18 |
| Atenolol | Atenolol | 29 | suppressed |
| Dantrolene Sodium | Dantrolene Sodium | 29 | suppressed |
| Digoxin | Digoxin | 29 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 29 | suppressed |
| Lamotrigine | Lamotrigine | 28 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 27 | 14 |
| Diltiazem 24hr Er | Diltiazem Hcl | 26 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 26 | suppressed |
| Nystatin | Nystatin | 26 | 17 |
| Venlafaxine Hcl | Venlafaxine Hcl | 26 | suppressed |
| Nyamyc | Nystatin | 25 | 17 |
| Oxybutynin Chloride | Oxybutynin Chloride | 25 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 25 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 25 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 25 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 25 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 24 | 17 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 24 | 13 |
| Enulose | Lactulose | 24 | suppressed |
| Pregabalin | Pregabalin | 24 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 24 | 13 |
| Bupropion Hcl Sr | Bupropion Hcl | 23 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 23 | 13 |
| Glipizide | Glipizide | 23 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 23 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 23 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 22 | suppressed |
| Clonazepam | Clonazepam | 22 | suppressed |
| Fenofibrate | Fenofibrate | 22 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 22 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 22 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 22 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 22 | suppressed |
| Sodium Bicarbonate | Sodium Bicarbonate | 22 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 21 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 21 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 21 | suppressed |
| Levalbuterol Hcl | Levalbuterol Hcl | 21 | suppressed |
| Velphoro | Sucroferric Oxyhydroxide | 21 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 20 | suppressed |
| Baclofen | Baclofen | 20 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 20 | 14 |
| Liothyronine Sodium | Liothyronine Sodium | 20 | suppressed |
| Carbamazepine | Carbamazepine | 19 | suppressed |
| Primidone | Primidone | 19 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 18 | 18 |
| Fluconazole | Fluconazole | 18 | 11 |
| Glipizide Er | Glipizide | 18 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 18 | suppressed |
| Metolazone | Metolazone | 18 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 18 | suppressed |
| Carbamazepine Er | Carbamazepine | 17 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 17 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 17 | suppressed |
| Nifedipine Er | Nifedipine | 17 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 17 | 11 |
| Bupropion Xl | Bupropion Hcl | 16 | suppressed |
| Dulera | Mometasone/Formoterol | 16 | suppressed |
| Eplerenone | Eplerenone | 16 | suppressed |
| Ezetimibe | Ezetimibe | 16 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 16 | suppressed |
| Nitroglycerin | Nitroglycerin | 16 | 13 |
| Zolpidem Tartrate | Zolpidem Tartrate | 16 | suppressed |
| Amoxicillin | Amoxicillin | 15 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Lidocaine | Lidocaine | 15 | suppressed |
| Colchicine | Colchicine | 14 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 14 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 14 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 14 | suppressed |
| Xifaxan | Rifaximin | 14 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 13 | suppressed |
| Gemfibrozil | Gemfibrozil | 13 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 13 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 13 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 13 | suppressed |
| Alprazolam | Alprazolam | 12 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 12 | suppressed |
| Cimetidine | Cimetidine | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 12 | suppressed |
| Dutasteride | Dutasteride | 12 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 12 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 12 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 12 | suppressed |
| Ertapenem | Ertapenem Sodium | 11 | suppressed |
| Levemir Flexpen | Insulin Detemir | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $136.15 · 5 records | Janssen Pharmaceuticals, Inc | INGREZZA, INVEGA SUSTENNA, INVEGA TRINZA, REXULTI, Wegovy | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Invega Sustenna play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Janssen Pharmaceuticals, Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error